Glioblastoma Multiforme Therapeutics Market Forecasts to 2019

Information about Glioblastoma Multiforme Therapeutics Market Forecasts to 2019

Published on July 24, 2014

Author: alan_hyes

Source: authorstream.com

Content

PowerPoint Presentation: Price: Single User: US$3500 Corporate User: US$10500 Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany PowerPoint Presentation: A leading business intelligence provider, has released its latest research report, "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany".Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar ( temozolomide ), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin ( bevacizumab ), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. The market entry of Northwest Biotherapeutics ' DCVax -L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany Complete report available @ http://www.reportsnreports.com/reports/287911-glioblastoma-multiforme-therapeutics-in-major-developed-markets-to-2019-growth-to-hinge-on-the-success-of-personalized-vaccine-following-early-approval-in-germany.html . PowerPoint Presentation: Scope A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain Discussion of the drivers of and barriers to market growth Discussion of the licensing and co-development deals landscape in GBM Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=287911 . PowerPoint Presentation: Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7 2 Introduction 8 2.1 Disease Introduction 8 2.2 Classification of Brain Tumors 9 2.3 Tumor Grading 11 2.4 Subtypes of Glioblastoma Multiforme 12 2.5 Etiology 12 2.6 Pathophysiology 13 2.6.1 Loss of Heterozygosity of Chromosome 10 14 2.6.2 Epidermal Growth Factor Receptor Amplification 14 2.6.3 Phosphatase and Tensin Homolog Mutation 14 2.6.4 Loss of p53 Function 15 2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function 15 2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation 15 2.7 Symptoms 16 2.8 Diagnosis 17 2.9 Prognosis 18 2.10 Epidemiology 19 Browse more research reports Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ . Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany PowerPoint Presentation: 2 Introduction 8 2.11 Treatment options 20 2.11.1 Surgery 20 2.11.2 Radiotherapy 20 2.11.3 Chemotherapy 21 2.11.4 Targeted Therapy 22 2.11.5 Drugs for symptoms relief 22 2.11.6 Other alternative therapies 22 2.12 Treatment algorithm 23 3 Marketed drugs 26 3.1 Temodar ( temozolomide ) - Merck 26 3.2 Avastin ( bevacizumab ) - Roche 28 3.3 BiCNU ( carmustine ) and Gliadel Wafer ( carmustine in polifeprosan ) 30 3.3.1 BiCNU ( carmustine ) - Bristol-Myers Squibb 31 3.3.2 Gliadel Wafer ( carmustine in polifeprosan ) - Eisai 32 3.4 Unlicensed/Off-label Use in Glioblastoma Multiforme 34 3.4.1 Lomustine 34 3.4.2 Carboplatin 34 3.4.3 Cyclophosphamide 34 3.4.4 Etoposide 35 3.4.5 Irinotecan 35 Browse more research reports Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ . Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany PowerPoint Presentation: Reasons to buy Understand the different levels of Glioblastoma Multiforme Therapeutics therapies for newly diagnosed and recurrent GBM Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market Inquire for a discount on this report @ http://www.reportsnreports.com/contacts/discount.aspx?name=287911 . Browse more research reports Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ . Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany PowerPoint Presentation: ReportsnReports.com  is your single source for all market research needs. Our database includes 250,000+ syndicated market research reports from 100+ leading global publishers covering in-depth analysis of over 5000 micro markets. With comprehensive information about the publishers and their report methodology, data sources, etc. we help you in your purchase decision by mapping your information needs with the most relevant available reports in our library. Connect with us: [email protected] + 1 888 391 5441 About ReportsnReports Contact:  [email protected]  for further information. Contact:  [email protected]  for further information .

Related presentations


Other presentations created by alan_hyes